Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

MDX-CD4 development progresses, triggering milestone payment from Eisai

Sep. 7, 1998

Substituted pyrimidines from Amgen inhibit cytokine production

Sep. 7, 1998

Antiadhesion agents prepared and evaluated at Hoechst

Sep. 7, 1998

MMP inhibitors in early development at British Biotech

Sep. 7, 1998

Dual 5-LO and COX-2 inhibitors for inflammatory disorders

Sep. 3, 1998

Zeneca patents new peptides for autoimmune/inflammatory disorders

Sep. 2, 1998

New treatment for osteoarthritis pain now available in the U.K.

Aug. 31, 1998

New agent for the prevention of osteoarthritis identified at Roche Bioscience

Aug. 27, 1998

MMP inhibitors under investigation at Pharmacia & Upjohn

Aug. 27, 1998

FDA gives priority review status to COX-2 inhibitor

Aug. 27, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....